73295-12-2

Basic information

• Product Name: (S)-2,3-DiMethyl-1,3-butanediol
• Synonyms: (2S)-2,3-DiMethyl-1,3-butanediol;(S)-2,3-DiMethyl-1,3-butanediol;(S)-2,3-diMethylbutane-1,3-diol;(2S)-2,3-Dimethylbutane-1,3-diol;(2S),3-Dimethyl-butane-1,3-diol
• CAS NO: 73295-12-2
• Molecular Formula: C₆H₁₄O₂
• Molecular Weight: 118.17416
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 73295-12-2.mol

Chemical Properties

• Boiling Point: 200.9°C at 760 mmHg
• Flash Point: 87.9°C
• Appearance: /
• Density: 0.96g/cm³
• Vapor Pressure: 0.0785mmHg at 25°C
• Refractive Index: 1.446
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• PKA: 14.95±0.29(Predicted)
• CAS DataBase Reference: (S)-2,3-DiMethyl-1,3-butanediol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2,3-DiMethyl-1,3-butanediol(73295-12-2)
• EPA Substance Registry System: (S)-2,3-DiMethyl-1,3-butanediol(73295-12-2)

Safety Data

• Hazardous Substances Data: 73295-12-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2,3-DiMethyl-1,3-butanediol is used as an intermediate in the synthesis of Vitamin D2 and its derivatives. It plays a crucial role in the production process due to its unique chemical structure, which allows for the creation of essential vitamins that are vital for human health.
Used in Chemical Industry:
As a colorless liquid, (S)-2,3-DiMethyl-1,3-butanediol can also be utilized in various chemical applications, such as the production of specialty chemicals, additives, and other compounds that require its specific properties. Its versatility in chemical reactions makes it a valuable component in the development of new materials and products.

InChI:InChI=1/C6H14O2/c1-5(4-7)6(2,3)8/h5,7-8H,4H2,1-3H3/t5-/m0/s1

Upstream product

• 93748-46-0 (S)-4-Benzyloxy-2,3-dimethyl-butan-2-ol 
• 556-82-1 3-methyl-2-buten-1-ol 
• 80657-57-4 3-hydroxy-(2S)-methylpropionate 
• 23985-53-7 (R)-3-hydroxy-2,3-dimethylbutansaeure 
• 676-58-4 methylmagnesium chloride 
• 71312-15-7 1-benzyloxy-2,3-epoxy-3-methylbutane 
• 62748-09-8 [(2R)-3,3-dimethyloxiran-2-yl]methanol 
• 75-16-1 methylmagnesium bromide 
• 917-54-4 methyllithium 
• 917-64-6 methyl magnesium iodide 
• 73295-10-0 (S)-3-acetoxy-2-methyl-propionic acid methyl ester 

Downstream Products

• 1246949-46-1 C₂₂H₃₂O₂Si 
• 93748-48-2 (S)-3-hydroxy-2,3-dimethylbutyl 4-methylbenzenesulfonate 
• 1402710-06-8 C₄₅H₇₈O₆SSi₂ 
• 131918-61-1 paricalcitol 
• 1192803-39-6 C₃₉H₇₂O₃Si₂ 
• 1246949-36-9 C₂₇H₄₀O₃Si 
• 1246949-39-2 (3α,5α,11β,17ξ,22S,24S)-3,11-bis(benzyloxy)-24-methyl-22,25-epoxyfurostan-20-ol 
• 1246949-28-9 C₄₇H₆₆O₆ 
• 21343-40-8 ercalcidiol 
• 93775-08-7 (2S,5R)-4-Benzenesulfonyl-2-[(3S,9S,10R,13R,14R,17R)-10,13-dimethyl-3-(tetrahydro-pyran-2-yloxy)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-5,6-dimethyl-6-(tetrahydro-pyran-2-yloxy)-heptan-3-ol 
• 95716-68-0 cis-6-methyl-7-(5-hydroxy-1,4,5-trimethyl-2-hexenyl)-2,3,3a,6,7,7a-hexahydroindan-4(5H)-one 
• 95716-68-0 6-methyl-7-(5-hydroxy-1,4,5-trimethyl-2-hexenyl)-2,3,3a,6,7,7a-hexahydroindan-4(5H)-one 
• 142700-37-6 2,3-dimethyl-3-(phenylmethoxy)-5-hepten-4-ol 
• 142700-36-5 2,3-dimethyl-3-(phenylmethoxy)-5-hepten-4-ol 

Relevant articles and documents

Efficient synthesis of 3-TBDMS-11α,25-dihydroxyvitamin D3 and D2 ethers

Vitamin D deficiency might cause a wide variety of human disorders. As a prerequisite for appropriate diagnosis and therapy, medicinally relevant vitamin D metabolites have to be assayed most accurately and with high specificity. It has been demonstrated, that vitamin D conjugates, linked via a hydroxyl group at C11, might be promising for the development of highly specific antibodies to be employed in competitive protein binding assays. The connective synthesis of 3-TBDMS-11α,25-dihydroxyvitamin D3 and D2 ethers in 500 mg scale, starting from vitamin D2, is described. For installation of a hydroxyl group at C11 a sequence of Pd(OAc)2 mediated oxidation of an enone, epoxidation and subsequent epoxide ring opening was applied to obtain a suitable CD-ring precursor, that was connected with an A-ring diphenylphosphine oxide by Wittig-Horner reaction. Finally, an appropriate side chain was installed, respectively.

Preparation method of paricalcitol intermediate

The invention relates to a preparation method of a paricalcitol intermediate, in particular to a preparation method for an intermediate (as shown in a formula (I)) for synthesizing paricalcitol (II). According to the method, a chiral intermediate as shown in a formula (V) through anti-and syn-aldol reaction of a chiral compound as shown in a formula (IV) and acetone, and the intermediate (as shown in a formula (I)) for synthesizing the paricalcitol is obtained through reduction, halogenations and reaction with triphenyl phosphine. The method has the advantages of mild reaction condition, simplicity and convenience in operation, high optical purity, low synthesis cost and the like, and is suitable for large-scale production. (The formulas are as shown in the description.).

A volatile lactone of Hymenoscyphus pseudoalbidus, pathogen of European ash dieback, inhibits host germination

The largely unknown secondary metabolism of the plant pathogenic fungus Hymenoscyphus pseudoalbidus was investigated by use of the CLSA method. A set of volatile lactones was identified by GC/MS. The lactones were synthesized and used in bioassays in which one of the compounds was found to be a strong germination inhibitor for ash seeds, causing necroses in the plant tissue. The largely unknown secondary metabolism of the plant pathogenic fungus Hymenoscyphus pseudoalbidus was investigated by use of the closed-loop stripping apparatus (CLSA) method. A set of volatile lactones was identified by GC/MS. The lactones were synthesized and used in bioassays in which one of the compounds was found to be a strong germination inhibitor for ash seeds.

Synthesis and crystallographic study of 1,25-dihydroxyergocalciferol analogs

The hybrid analogs of 1,25-dihydroxyergocalciferol (PRI-5201 and PRI-5202) were synthesized as potential anticancer agents using a convergent strategy. The analogs were designed by combining a 19-nor modification of the A-ring with the homologated and rig

METHODS FOR PRODUCING PARICALCITOL

The present invention is directed to novel processes for the preparation of paricalcitol to novel intermediates used in these processes, and to processes for preparation of the novel intermediates.

Process for preparation of paricalcitol and intermediates thereof

The invention relates to a novel process for the preparation of Paricalcitol and intermediates thereof.

Electrophilic Cyclization of 1,6-Dienes Containing an Allylsilane Moiety - Enantioselective Synthesis of cis- and trans-γ-Irone

In this paper, we report the first examples of Lewis acid and mercuric trifluoroacetate promoted cyclizations of 1,6-dienes containing an allylsilane moiety. Mercuric trifluoroacetate has been proved to be the reagent of choice leading to methylenecyclohexane derivatives in good yields and with complete regioselectivity albeit with poor diastereoselectivity. Using this methodology a stereodivergent synthesis of enantiomerically pure (-)-(2S,6R)-cis-γ -irone and (-)-(2S,6S)-trans-γ-irone, two precious aroma constituents, has been accomplished. This represents an innovative approach with respect to previous syntheses of γ-irones. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003.

Phosphorus ylide chemistry investigated for dihydrotachysterol2 metabolite side-chain synthesis: The Wittig approach

The behaviour of the γ-oxido ylide of R-(3-hydroxy-2,3-dimethylbutyl)triphenylphosphonium iodide 4, to be used in the 25-hydroxylated DHT2 side-chain synthesis, was studied. The synthesis of the chiral phosponium salt 4 was done in an overall y

An Intramolecular Diels-Alder Approach to the Cis Ring Fused Isomer of the 25-Hydroxy Vitamin D2 Grundmann Ketone

Stereospecific Claisen and intramolecular Diels-Alder reactions of chiral ester synthon 4 results in conversion of a single asymmetric center of commercially available ester 4 to a vitamin D synthon, the C/D cis Grundmann ketone 3.The addition of propenyl

1α,25-dihydroxyvitamin D4 compounds, ergosta-5,7-diene compounds and processes for the preparation thereof

(24S)- and (24R)-1α,25-Dihydroxyvitamin D4 compounds and processes for preparing same. Ergosta-5,7-diene compounds which are useful intermediates in the synthesis of the 1α,25-dihydroxyvitamin D4 compounds. The D4 compounds are expected to possess an interesting pharmacological activity in association with the active-type vitamins D3 and D2.